Stay updated on Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page.

Latest updates to the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 appears in the page footer across the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoChange DetectedA site-wide operating-status notice about government funding and NIH operations has been removed from the page.SummaryDifference0.4%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedCore study content, including objectives, endpoints, and eligibility criteria, appears unchanged; only minor formatting/layout adjustments are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check54 days agoChange DetectedUpdate includes a government-operating-status notice and a version bump from v3.1.0 to v3.2.0. No changes to core product data like prices or stock are indicated.SummaryDifference4%

- Check61 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded a new MedlinePlus Genetics topic on Lung cancer; overall content expansion in genetics/medical topics.SummaryDifference0.3%

Stay in the know with updates to Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine+Nivolumab in Metastatic Small Cell Lung Cancer Clinical Trial page.